Cristin L. Rothfuss - 26 Nov 2024 Form 3 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
EVP, General Counsel
Signature
/s/ Cristin Rothfuss
Issuer symbol
SRPT
Transactions as of
26 Nov 2024
Net transactions value
$0
Form type
3
Filing time
29 Nov 2024, 20:00:04 UTC
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SRPT Common Stock 11,817 26 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 5,050 $133.76 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 216 $90.15 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 2,525 $114.47 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 1,200 $118.52 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 1,563 $87.11 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 1,248 $87.11 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 4,197 $80.42 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 5,900 $155.99 Direct F1
holding SRPT Stock Option (Right to buy) 26 Nov 2024 Common Stock 6,200 $128.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter.